دورية أكاديمية
Continuity of care for patients with de novo metastatic cancer during the COVID-19 pandemic: A population-based observational study.
| العنوان: | Continuity of care for patients with de novo metastatic cancer during the COVID-19 pandemic: A population-based observational study. |
|---|---|
| المؤلفون: | Slotman E; Technical Medical Centre, Department of Health Technology and Services Research, University of Twente, Enschede, Netherlands.; Department of Research and Development, Netherlands Comprehensive Cancer Organisation, Utrecht, Netherlands.; Netherlands Association for Palliative Care, Utrecht, Netherlands., Weijzen F; Technical Medical Centre, Department of Health Technology and Services Research, University of Twente, Enschede, Netherlands., Fransen HP; Department of Research and Development, Netherlands Comprehensive Cancer Organisation, Utrecht, Netherlands.; Netherlands Association for Palliative Care, Utrecht, Netherlands., van Hoeve JC; Technical Medical Centre, Department of Health Technology and Services Research, University of Twente, Enschede, Netherlands.; Department of Research and Development, Netherlands Comprehensive Cancer Organisation, Utrecht, Netherlands., Huijben AMT; Department of Internal Medicine, Maasstad Hospital, Rotterdam, Netherlands., Kuip EJM; Department of Medical Oncology and Department of Anesthesiology, Pain and Palliative Care, Radboud Medical Center, Nijmegen, Netherlands., Jager A; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, Netherlands., Kunst PWA; Department of Research and Development, Netherlands Comprehensive Cancer Organisation, Utrecht, Netherlands.; Department of Pulmonology, Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands., van Laarhoven HWM; Medical Oncology, Amsterdam UMC location University of Amsterdam, Amsterdam, Netherlands.; Cancer Treatment and Quality of Life, Cancer Center Amsterdam, Amsterdam, Netherlands., Tol J; Department of Internal Medicine, Jeroen Bosch Hospital, 's-Hertogenbosch, Netherlands., Tjan-Heijnen VCG; Department of Medical Oncology, Research Institute GROW, Maastricht University Medical Centre, Maastricht, Netherlands., Raijmakers NJH; Department of Research and Development, Netherlands Comprehensive Cancer Organisation, Utrecht, Netherlands.; Netherlands Association for Palliative Care, Utrecht, Netherlands., van der Linden YM; Department of Research and Development, Netherlands Comprehensive Cancer Organisation, Utrecht, Netherlands.; Department of Radiotherapy, Leiden University Medical Centre, Leiden, Netherlands.; Centre of Expertise in Palliative Care, Leiden University Medical Centre, Leiden, Netherlands., Siesling S; Technical Medical Centre, Department of Health Technology and Services Research, University of Twente, Enschede, Netherlands.; Department of Research and Development, Netherlands Comprehensive Cancer Organisation, Utrecht, Netherlands. |
| مؤلفون مشاركون: | On-behalf-of-the-COVID-and-Cancer-NL Consortium |
| المصدر: | International journal of cancer [Int J Cancer] 2024 May 15; Vol. 154 (10), pp. 1786-1793. Date of Electronic Publication: 2024 Jan 24. |
| نوع المنشور: | Observational Study; Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Wiley-Liss Country of Publication: United States NLM ID: 0042124 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-0215 (Electronic) Linking ISSN: 00207136 NLM ISO Abbreviation: Int J Cancer Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 1995- : New York, NY : Wiley-Liss Original Publication: 1966-1984 : Genève : International Union Against Cancer |
| مواضيع طبية MeSH: | COVID-19* , Neoplasms*, Humans ; Pandemics ; Continuity of Patient Care |
| مستخلص: | During the COVID-19 pandemic recommendations were made to adapt cancer care. This population-based study aimed to investigate possible differences between the treatment of patients with metastatic cancer before and during the pandemic by comparing the initial treatments in five COVID-19 periods (weeks 1-12 2020: pre-COVID-19, weeks 12-20 2020: 1st peak, weeks 21-41 2020: recovery, weeks 42-53 2020: 2nd peak, weeks 1-20 2021: prolonged 2nd peak) with reference data from 2017 to 2019. The proportion of patients receiving different treatment modalities (chemotherapy, hormonal therapy, immunotherapy or targeted therapy, radiotherapy primary tumor, resection primary tumor, resection metastases) within 6 weeks of diagnosis and the time between diagnosis and first treatment were compared by period. In total, 74,208 patients were included. Overall, patients were more likely to receive treatments in the COVID-19 periods than in previous years. This mainly holds for hormone therapy, immunotherapy or targeted therapy and resection of metastases. Lower odds were observed for resection of the primary tumor during the recovery period (OR 0.87; 95% CI 0.77-0.99) and for radiotherapy on the primary tumor during the prolonged 2nd peak (OR 0.84; 95% CI 0.72-0.98). The time from diagnosis to the start of first treatment was shorter, mainly during the 1st peak (average 5 days, p < .001). These findings show that during the first 1.5 years of the COVID-19 pandemic, there were only minor changes in the initial treatment of metastatic cancer. Remarkably, time from diagnosis to first treatment was shorter. Overall, the results suggest continuity of care for patients with metastatic cancer during the pandemic. (© 2024 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.) |
| References: | Lambooij M, Heins M, Meijer M, Vader S, de Jong J, Janssen L. Het mijden van huisartsenzorg tijdens de coronapandemie. Inzicht in verminderde huisartsenzorg tijdens de coronapandemie [Avoiding GP Care during the Coronavirus Pandemic Insight in Reduction of GP Care during the Coronavirus Pandemic]. Rijksinstituut voor Volksgezondheid en Milieu RIVM; 2022. Ruiz-Medina S, Gil S, Jimenez B, et al. Significant decrease in annual cancer diagnoses in Spain during the COVID-19 pandemic: a real-data study. Cancers (Basel). 2021;13(13):3215. doi:10.3390/cancers13133215. Jacob L, Loosen SH, Kalder M, Luedde T, Roderburg C, Kostev K. Impact of the COVID-19 pandemic on cancer diagnoses in general and specialized practices in Germany. Cancers (Basel). 2021;13(3):408. doi:10.3390/cancers13030408. Marques NP, Silveira DMM, Marques NCT, Martelli DRB, Oliveira EA, Martelli-Júnior H. Cancer diagnosis in Brazil in the COVID-19 era. Semin Oncol. 2021;48(2):156-159. doi:10.1053/j.seminoncol.2020.12.002. Peacock HM, Tambuyzer T, Verdoodt F, et al. Decline and incomplete recovery in cancer diagnoses during the COVID-19 pandemic in Belgium: a year-long, population-level analysis. ESMO Open. 2021;6(4):100197. doi:10.1016/j.esmoop.2021.100197. Dinmohamed AG, Visser O, Verhoeven RH, et al. Fewer cancer diagnoses during the COVID-19 epidemic in the Netherlands. Lancet Oncol. 2020;21(6):750-751. de Joode K, Dumoulin DW, Engelen V, et al. Impact of the coronavirus disease 2019 pandemic on cancer treatment: the patients' perspective. Eur J Cancer. 2020;136:132-139. doi:10.1016/j.ejca.2020.06.019. Deukeren DV, Heesterman BL, Roelofs L, et al. Impact of the COVID-19 outbreak on prostate cancer care in the Netherlands. Cancer Treat Res Commun. 2022;31:100553. doi:10.1016/j.ctarc.2022.100553. Meijer J, Elferink MAG, Vink GR, et al. Limited impact of the COVID-19 pandemic on colorectal cancer care in the Netherlands in 2020. Int J Colorectal Dis. 2022;37(9):2013-2020. doi:10.1007/s00384-022-04209-4. Schoonbeek RC, de Jel DVC, van Dijk BAC, et al. Fewer head and neck cancer diagnoses and faster treatment initiation during COVID-19 in 2020: a nationwide population-based analysis. Radiother Oncol. 2022;167:42-48. doi:10.1016/j.radonc.2021.12.005. Van Hoogstraten LMC, Kiemeney LA, Meijer RP, et al. The impact of the COVID-19 pandemic on bladder cancer care in the Netherlands. Bladder Cancer. 2022;8:139-154. doi:10.3233/BLC-211608. Eijkelboom AH, de Munck L, der Houven M-v, et al. Changes in breast cancer treatment during the COVID-19 pandemic: a Dutch population-based study. Breast Cancer Res Treat. 2023;197(1):161-175. doi:10.1007/s10549-022-06732-y. Eijkelboom AH, de Munck L, Peeters M-JTV, et al. Impact of the COVID-19 pandemic on diagnosis, stage, and initial treatment of breast cancer in the Netherlands: a population-based study. J Hematol Oncol. 2021;14(1):1-12. IKNL. uitgezaaide kanker in beeld. Accessed January 20, 2023. https://iknl.nl/getmedia/6ddb80c4-254f-4763-943f-1a50f5321b83/uitgezaaide-kanker-in-beeld-rapport.pdf. Fedele P, Ferro A, Sanna V, La Verde N, Paris I, Chiari R. Exploring metastatic breast cancer treatment changes during COVID-19 pandemic. J Chemother. 2021;33(4):263-268. doi:10.1080/1120009x.2020.1829328. Parikh RB, Takvorian SU, Vader D, et al. Impact of the COVID-19 pandemic on treatment patterns for patients with metastatic solid cancer in the United States. J Natl Cancer Inst. 2022;114(4):571-578. doi:10.1093/jnci/djab225. van Not OJ, van Breeschoten J, van den Eertwegh AJM, et al. The unfavorable effects of COVID-19 on Dutch advanced melanoma care. Int J Cancer. 2022;150(5):816-824. doi:10.1002/ijc.33833. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-383. doi:10.1016/0021-9681(87)90171-8. Rijksoverheid. Coronavirus Dashboard: View on the Hospitals. Accessed February 21, 2023. https://coronadashboard.government.nl/landelijk/ziekenhuizen-en-zorg. SONCOS. Multidisciplinaire normering oncologische zorg in Nederland [Multidisciplinary Standards Oncological Care in The Netherlands]. 2022. Accessed February 21, 2023. https://www.soncos.org/. Ismail RK, Schramel F, van Dartel M, et al. The Dutch lung cancer audit: nationwide quality of care evaluation of lung cancer patients. Lung Cancer. 2020;149:68-77. doi:10.1016/j.lungcan.2020.08.011. Halwani AS, Rasmussen KM, Patil V, et al. Real-world practice patterns in veterans with metastatic castration-resistant prostate cancer. Urol Oncol. 2020;38(1):1.e1-1.e10. doi:10.1016/j.urolonc.2019.09.027. Ritch CR, Cookson MS. Advances in the management of castration resistant prostate cancer. BMJ. 2016;355:i4405. Luyendijk M, Visser O, Blommestein HM, et al. Changes in survival in de novo metastatic cancer in an era of new medicines. J Natl Cancer Inst. 2023;115:628-635. doi:10.1093/jnci/djad020. Conti A, Acker G, Kluge A, et al. Decision making in patients with metastatic spine. The role of minimally invasive treatment modalities. Front Oncol. 2019;9:915. doi:10.3389/fonc.2019.00915. Pennington Z, Ahmed AK, Molina CA, Ehresman J, Laufer I, Sciubba DM. Minimally invasive versus conventional spine surgery for vertebral metastases: a systematic review of the evidence. Ann Transl Med. 2018;6(6):103. doi:10.21037/atm.2018.01.28. Eijkelboom AH, de Munck L, Lobbes MBI, et al. Impact of the suspension and restart of the Dutch breast cancer screening program on breast cancer incidence and stage during the COVID-19 pandemic. Prev Med. 2021;151:106602. doi:10.1016/j.ypmed.2021.106602. Toes-Zoutendijk E, Vink G, Nagtegaal ID, et al. Impact of COVID-19 and suspension of colorectal cancer screening on incidence and stage distribution of colorectal cancers in the Netherlands. Eur J Cancer. 2022;161:38-43. doi:10.1016/j.ejca.2021.11.008. Zee MS, Bagchus L, Becqué YN, et al. Impact of COVID-19 on care at the end of life during the first months of the pandemic from the perspective of healthcare professionals from different settings: a qualitative interview study (the CO-LIVE study). BMJ Open. 2023;13(3):e063267. Dujardin J, Schuurmans J, Westerduin D, Wichmann AB, Engels Y. The COVID-19 pandemic: a tipping point for advance care planning? Experiences of general practitioners. Palliat Med. 2021;35(7):1238-1248. doi:10.1177/02692163211016979. Funk DC, Moss AH, Speis A. How COVID-19 changed advance care planning: insights from the West Virginia Center for End-of-Life Care. J Pain Symptom Manage. 2020;60(6):e5-e9. doi:10.1016/j.jpainsymman.2020.09.021. Curtis JR, Kross EK, Stapleton RD. The importance of addressing advance care planning and decisions about do-not-resuscitate orders during novel coronavirus 2019 (COVID-19). JAMA. 2020;323(18):1771-1772. doi:10.1001/jama.2020.4894. |
| معلومات مُعتمدة: | 10430022010014 Netherlands ZONMW_ ZonMw |
| فهرسة مساهمة: | Keywords: COVID-19; metastatic cancer; treatment |
| تواريخ الأحداث: | Date Created: 20240125 Date Completed: 20240314 Latest Revision: 20240314 |
| رمز التحديث: | 20240314 |
| DOI: | 10.1002/ijc.34857 |
| PMID: | 38268393 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1097-0215 |
|---|---|
| DOI: | 10.1002/ijc.34857 |